Quote:Under the commercialisation and licence agreement between...

Quote:Under the commercialisation and licence agreement between Biota and Daiichi Sankyo, the parties will share commercial returns from licensing outside Japan.

This is indeed an exciting start of a flagship product for BTA that has the potential to put Tamiflu and Relenza in its shadow. It is good to see that Sankyo will have a say in licensing outside of Japan. Daiichi Sankyo had indeed proven themselves to be a much more enthusiastic partner than GSK. After Peter Molloy, the former CEO launched the partnership with DS in 2004, Daiichi Sankyo had work tirelessly and met expectations in bringing LANI to market. Well done Peter Molloy and Daiichi Sankyo for the success.

The market has yet to caught up with the Relenza royalties, let alone value this drug-buster. Although the LANI trial has to be replicated in other markets (UK and the US), I believe it is a mere formality. I admit I have no experience or knowledge of drug trials, but surely the success in the Japanese trials must be easily repeated in the US and UK. Perhaps someone else maybe able to enlighten us as to whether there is any history of a drug successfully completing Phase 3 trials in one market could not be repeated elsewhere.

We will not have to wait long for the market to wake up to the dawn of this new flagship product.